Maryland State Retirement & Pension System Buys 182 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Maryland State Retirement & Pension System raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,069 shares of the biopharmaceutical company’s stock after purchasing an additional 182 shares during the period. Maryland State Retirement & Pension System’s holdings in Regeneron Pharmaceuticals were worth $2,661,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after acquiring an additional 89,579 shares in the last quarter. Amundi increased its position in shares of Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock worth $979,794,000 after acquiring an additional 52,166 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.1% during the first quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock worth $458,211,000 after acquiring an additional 14,921 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on REGN. Sanford C. Bernstein boosted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Argus downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday. UBS Group reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research report on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $817.46.

Regeneron Pharmaceuticals Stock Down 0.9%

REGN opened at $564.63 on Friday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The stock has a market cap of $59.85 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 1.82 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,024.36. The company’s 50-day moving average price is $573.95 and its two-hundred day moving average price is $565.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company earned $11.56 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.